(SEM) Select Medical Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US81619Q1058
Stock: Hospitals, Clinics, Therapy, Care
Total Rating 39
Risk 70
Buy Signal -0.42
| Risk 5d forecast | |
|---|---|
| Volatility | 36.9% |
| Relative Tail Risk | -14.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.03 |
| Alpha | -28.36 |
| Character TTM | |
|---|---|
| Beta | 1.396 |
| Beta Downside | 1.665 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.06% |
| CAGR/Max DD | 0.17 |
EPS (Earnings per Share)
Revenue
Description: SEM Select Medical Holdings February 28, 2026
Select Medical Holdings Corp. (NYSE: SEM) operates a network of critical-illness recovery hospitals, rehabilitation hospitals, and outpatient rehab clinics across the United States. Its Critical Illness Recovery segment treats patients with heart failure, respiratory failure, renal disease, neurological events and trauma, while the Rehabilitation Hospital segment focuses on therapy for brain/spinal injuries, strokes, orthopedic and cancer-related conditions. The Outpatient Rehabilitation segment delivers physical, occupational and speech services plus specialty programs such as hand therapy, pelvic health and post-concussion care.
In its most recent fiscal year (2023), SEM reported revenue of $2.1 billion, a 7% YoY increase driven by higher occupancy in its acute-care hospitals (average 84% versus the industry median of 78%) and strong growth in outpatient visits (+12%). Adjusted EBITDA margin expanded to 13.5%, reflecting improved cost efficiencies and favorable Medicare Advantage reimbursement trends. The broader health-care facilities sector is being propelled by an aging U.S. population-people aged 65+ are projected to reach 21% of the total by 2030-fueling demand for post-acute and rehabilitative services.
For a deeper dive into SEM’s valuation and how these trends may affect its outlook, you might explore ValueRay’s analysis.
Headlines to watch out for
- Hospital occupancy rates directly impact revenue
- Reimbursement rates from government and private payers are crucial
- Labor costs, especially for skilled medical staff, affect profitability
- Regulatory changes in healthcare policy create uncertainty
- Economic downturns reduce elective outpatient rehabilitation demand
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 146.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.27 > 1.0 |
| NWC/Revenue: 0.75% < 20% (prev 0.89%; Δ -0.15% < -1%) |
| CFO/TA 0.06 > 3% & CFO 346.5m > Net Income 146.2m |
| Net Debt (3.68b) to EBITDA (530.6m): 6.93 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.5m) vs 12m ago -4.40% < -2% |
| Gross Margin: 10.88% > 18% (prev 0.11%; Δ 1.08k% > 0.5%) |
| Asset Turnover: 95.17% > 50% (prev 83.97%; Δ 11.19% > 0%) |
| Interest Coverage Ratio: 3.32 > 6 (EBITDA TTM 530.6m / Interest Expense TTM 117.6m) |
Altman Z'' 1.20
| A: 0.01 (Total Current Assets 1.03b - Total Current Liabilities 984.5m) / Total Assets 5.85b |
| B: 0.14 (Retained Earnings 837.0m / Total Assets 5.85b) |
| C: 0.07 (EBIT TTM 390.3m / Avg Total Assets 5.73b) |
| D: 0.22 (Book Value of Equity 830.7m / Total Liabilities 3.82b) |
| Altman-Z'' Score: 1.20 = BB |
Beneish M -3.00
| DSRI: 0.91 (Receivables 864.2m/821.4m, Revenue 5.45b/4.71b) |
| GMI: 1.04 (GM 10.88% / 11.29%) |
| AQI: 0.98 (AQ_t 0.49 / AQ_t-1 0.50) |
| SGI: 1.16 (Revenue 5.45b / 4.71b) |
| TATA: -0.03 (NI 146.2m - CFO 346.5m) / TA 5.85b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of SEM shares?
As of March 18, 2026, the stock is trading at USD 16.26 with a total of 2,377,279 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -0.31%, over three months by +8.79% and over the past year by -3.72%.
Over the past week, the price has changed by +0.00%, over one month by -0.31%, over three months by +8.79% and over the past year by -3.72%.
Is SEM a buy, sell or hold?
Select Medical Holdings has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy SEM.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.6 | 2.3% |
| Analysts Target Price | 16.6 | 2.3% |
SEM Fundamental Data Overview March 15, 2026
P/E Trailing = 14.0086
P/E Forward = 13.0548
P/S = 0.3696
P/B = 1.1816
P/EG = 2.2583
Revenue TTM = 5.45b USD
EBIT TTM = 390.3m USD
EBITDA TTM = 530.6m USD
Long Term Debt = 1.80b USD (from longTermDebt, last quarter)
Short Term Debt = 229.4m USD (from shortTermDebt, last quarter)
Debt = 3.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.68b USD (from netDebt column, last quarter)
Enterprise Value = 5.69b USD (2.02b + Debt 3.70b - CCE 26.5m)
Interest Coverage Ratio = 3.32 (Ebit TTM 390.3m / Interest Expense TTM 117.6m)
EV/FCF = 48.56x (Enterprise Value 5.69b / FCF TTM 117.2m)
FCF Yield = 2.06% (FCF TTM 117.2m / Enterprise Value 5.69b)
FCF Margin = 2.15% (FCF TTM 117.2m / Revenue TTM 5.45b)
Net Margin = 2.68% (Net Income TTM 146.2m / Revenue TTM 5.45b)
Gross Margin = 10.88% ((Revenue TTM 5.45b - Cost of Revenue TTM 4.86b) / Revenue TTM)
Gross Margin QoQ = 7.85% (prev 10.81%)
Tobins Q-Ratio = 0.97 (Enterprise Value 5.69b / Total Assets 5.85b)
Interest Expense / Debt = 0.77% (Interest Expense 28.6m / Debt 3.70b)
Taxrate = 25.21% (12.7m / 50.5m)
NOPAT = 291.9m (EBIT 390.3m * (1 - 25.21%))
Current Ratio = 1.04 (Total Current Assets 1.03b / Total Current Liabilities 984.5m)
Debt / Equity = 2.17 (Debt 3.70b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 6.93 (Net Debt 3.68b / EBITDA 530.6m)
Debt / FCF = 31.37 (Net Debt 3.68b / FCF TTM 117.2m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.55% (Net Income 146.2m / Total Assets 5.85b)
RoE = 8.62% (Net Income TTM 146.2m / Total Stockholder Equity 1.70b)
RoCE = 11.15% (EBIT 390.3m / Capital Employed (Equity 1.70b + L.T.Debt 1.80b))
RoIC = 8.29% (NOPAT 291.9m / Invested Capital 3.52b)
WACC = 4.27% (E(2.02b)/V(5.72b) * Re(11.06%) + D(3.70b)/V(5.72b) * Rd(0.77%) * (1-Tc(0.25)))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 88.43% ; FCFF base≈188.6m ; Y1≈232.7m ; Y5≈396.3m
[DCF] Fair Price = 63.39 (EV 11.54b - Net Debt 3.68b = Equity 7.86b / Shares 124.0m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -15.95 | EPS CAGR: -20.03% | SUE: -0.53 | # QB: 0
Revenue Correlation: -21.24 | Revenue CAGR: -3.55% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.29 | Chg7d=-0.000 | Chg30d=-0.013 | Revisions Net=-3 | Analysts=6
EPS current Year (2026-12-31): EPS=1.24 | Chg7d=-0.000 | Chg30d=-0.063 | Revisions Net=-4 | Growth EPS=+7.3% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=1.35 | Chg7d=-0.000 | Chg30d=-0.147 | Revisions Net=-2 | Growth EPS=+8.7% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 11.1% - Earnings Yield 7.1%)
[Growth] Growth Spread = +0.5% (Analyst 4.4% - Implied 3.9%)
P/E Forward = 13.0548
P/S = 0.3696
P/B = 1.1816
P/EG = 2.2583
Revenue TTM = 5.45b USD
EBIT TTM = 390.3m USD
EBITDA TTM = 530.6m USD
Long Term Debt = 1.80b USD (from longTermDebt, last quarter)
Short Term Debt = 229.4m USD (from shortTermDebt, last quarter)
Debt = 3.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.68b USD (from netDebt column, last quarter)
Enterprise Value = 5.69b USD (2.02b + Debt 3.70b - CCE 26.5m)
Interest Coverage Ratio = 3.32 (Ebit TTM 390.3m / Interest Expense TTM 117.6m)
EV/FCF = 48.56x (Enterprise Value 5.69b / FCF TTM 117.2m)
FCF Yield = 2.06% (FCF TTM 117.2m / Enterprise Value 5.69b)
FCF Margin = 2.15% (FCF TTM 117.2m / Revenue TTM 5.45b)
Net Margin = 2.68% (Net Income TTM 146.2m / Revenue TTM 5.45b)
Gross Margin = 10.88% ((Revenue TTM 5.45b - Cost of Revenue TTM 4.86b) / Revenue TTM)
Gross Margin QoQ = 7.85% (prev 10.81%)
Tobins Q-Ratio = 0.97 (Enterprise Value 5.69b / Total Assets 5.85b)
Interest Expense / Debt = 0.77% (Interest Expense 28.6m / Debt 3.70b)
Taxrate = 25.21% (12.7m / 50.5m)
NOPAT = 291.9m (EBIT 390.3m * (1 - 25.21%))
Current Ratio = 1.04 (Total Current Assets 1.03b / Total Current Liabilities 984.5m)
Debt / Equity = 2.17 (Debt 3.70b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 6.93 (Net Debt 3.68b / EBITDA 530.6m)
Debt / FCF = 31.37 (Net Debt 3.68b / FCF TTM 117.2m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.55% (Net Income 146.2m / Total Assets 5.85b)
RoE = 8.62% (Net Income TTM 146.2m / Total Stockholder Equity 1.70b)
RoCE = 11.15% (EBIT 390.3m / Capital Employed (Equity 1.70b + L.T.Debt 1.80b))
RoIC = 8.29% (NOPAT 291.9m / Invested Capital 3.52b)
WACC = 4.27% (E(2.02b)/V(5.72b) * Re(11.06%) + D(3.70b)/V(5.72b) * Rd(0.77%) * (1-Tc(0.25)))
Discount Rate = 11.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 88.43% ; FCFF base≈188.6m ; Y1≈232.7m ; Y5≈396.3m
[DCF] Fair Price = 63.39 (EV 11.54b - Net Debt 3.68b = Equity 7.86b / Shares 124.0m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -15.95 | EPS CAGR: -20.03% | SUE: -0.53 | # QB: 0
Revenue Correlation: -21.24 | Revenue CAGR: -3.55% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.29 | Chg7d=-0.000 | Chg30d=-0.013 | Revisions Net=-3 | Analysts=6
EPS current Year (2026-12-31): EPS=1.24 | Chg7d=-0.000 | Chg30d=-0.063 | Revisions Net=-4 | Growth EPS=+7.3% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=1.35 | Chg7d=-0.000 | Chg30d=-0.147 | Revisions Net=-2 | Growth EPS=+8.7% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 11.1% - Earnings Yield 7.1%)
[Growth] Growth Spread = +0.5% (Analyst 4.4% - Implied 3.9%)